TEVA Mar 2025 17.000 call
| Previous close | 2.6100 |
| Open | 2.4900 |
| Bid | 2.4200 |
| Ask | 2.6200 |
| Strike | 17.00 |
| Expiry date | 2025-03-21 |
| Day's range | 2.4900 - 2.5100 |
| Contract range | N/A |
| Volume | |
| Open interest | 220 |
Insider MonkeyDid Teva Pharmaceutical Industries Limited (TEVA)’s “Pivot to Growth” Strategy Help It Get a Positive Rating from Analysts?
We recently compiled a list of the 10 Best Robinhood Stocks Under $20. In this article, we are going to take a look at where Teva Pharmaceutical Industries Limited (NYSE:TEVA) stands against the other Robinhood stocks. The market reacted favorably after the Federal Reserve’s June 11-12 meeting. The broader market marked record closes. At the June […]
ReutersTeva sues Corcept over mifepristone 'monopoly' for rare disorder
Teva Pharmaceuticals sued rival drugmaker Corcept Therapeutics in federal court in San Francisco on Thursday, accusing it of monopolizing the market for mifepristone-based Korlym, used to treat a rare hormonal disorder called Cushing's syndrome. The lawsuit said Corcept and specialty pharmacy Optime Care, the sole distributor of Korlym, orchestrated “a multifaceted scheme to prolong Corcept’s monopoly by stifling competition from Teva at every turn.” Teva accused Corcept of "paying bribes and kickbacks" to physicians to keep them prescribing brand Korlym.
Business WireTeva to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
TEL AVIV, Israel, June 04, 2024--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024. The presentation will begin at 8:00 A.M. Eastern Time.
